Table 1 Demogaphic, clinical and laboratory data by FSGS pathologic variants
Total | NOS | Tip | Perihilar | Cellular | Collapsing | P† | ||
|---|---|---|---|---|---|---|---|---|
N (%) | 111 | 70 (63.1) | 20 (18.0) | 17 (15.3) | 3 (2.7) | 1 (0.9) | ||
Age (years) | 47.2 ± 16.2 | 48.0 ± 15.0 | 44.8 ± 16.9 | 45.1 ± 19.0 | 45.3 ± 18.2 | 84.0 | 0.649 | |
Sex | Male (%) | 44 (39.6) | 29 (41.4) | 7 (35.0) | 6 (35.3) | 2 (66.7) | 0 (0.0) | 0.818 |
Female (%) | 67 (60.4) | 41 (58.6) | 13 (65.0) | 11 (64.7) | 1 (33.3) | 1 (100.0) | ||
BMI (kg/m2) | 24.9 ± 3.9 | 24.8 ± 3.5 | 25.2 ± 4.5 | 25.3 ± 4.8 | 25.7 ± 4.2 | 23.8 | 0.837 | |
SBP (mmHg) | 133.1 ± 19.5 | 133.4 ± 19.8 | 133.8 ± 19.8 | 130.4 ± 17.3 | 140.0 ± 34.6 | 130.0 | 0.837 | |
DBP (mmHg) | 83.2 ± 15.7 | 83.9 ± 15.8 | 82.1 ± 11.9 | 81.4 ± 16.6 | 90.0 ± 35.3 | 72.0 | 0.784 | |
MAP (mmHg) | 99.9 ± 16.0 | 100.4 ± 16.2 | 99.3 ± 13.5 | 97.7 ± 15.6 | 106.8 ± 35.1 | 91.3 | 0.813 | |
Hypertension (%) | 63 (56.8) | 40 (57.1) | 9 (45.0) | 11 (64.7) | 2 (66.7) | 1 (100.0) | 0.462 | |
Hematuria (%) | 43 (38.7) | 28 (40.0) | 8 (40.0) | 6 (35.3) | 1 (33.3) | 0 (0.0) | 0.952 | |
Nephrotic range proteinuria (%) | 50 (45.0) | 27 (38.6) | 14 (70.0) | 5 (29.4) | 3 (100.0) | 1 (100.0) | 0.012 | |
Nephrotic syndrome (%) | 42 (37.8) | 22 (31.4) | 12 (60.0) | 7 (41.2) | 0 (0.0) | 1 (100.0) | 0.062 | |
Cr (mg/dL) | 1.28 ± 1.00 | 1.26 ± 0.81 | 0.97 ± 0.48 | 1.22 ± 0.52 | 2.11 ± 0.95 | 1.64 | 0.277 | |
eGFR (mL/min/1.73 m2) | 81.7 ± 33.0 | 81.4 ± 31.7 | 95.8 ± 34.3 | 75.8 ± 29.8 | 46.6 ± 23.4 | 37.8 | 0.202 | |
Serum albumin (g/dL) | 3.3 ± 1.0 | 3.4 ± 1.0 | 2.8 ± 1.0 | 3.7 ± 0.8 | 3.3 ± 0.6 | 1.9 | 0.018 | |
T- chol (mg/dL) | 248.3 ± 104.5 | 230.0 ± 89.6 | 340.6 ± 143.7 | 223.4 ± 52.7 | 204.0 ± 19.1 | 241.0 | <0.001 | |
LDL-chol (mg/dL) | 146.8 ± 80.2 | 137.5 ± 68.2 | 215.7 ± 114.1 | 109.6 ± 39.3 | 116.5 ± 17.9 | 162.0 | 0.002 | |
Proteinuria | ||||||||
UPCR (g/g)* | 3.02 (1.42-5.54) | 2.17 (1.33–5.10) | 4.67 (2.43-8.26) | 1.85 (0.95-4.24) | 5.54 (3.94-16.04) | 16.67 | 0.05 | |
24 hr protein (g/day)* | 2.90 (1.57-6.32) | 2.86 (1.32-5.73) | 4.28 (2.07-7.53) | 2.32 (0.95-5.20) | 4.12 (1.85-12.07) | 4.28 | 0.35 | |
TA-P (g/g)* | 1.41 (0.78-3.42) | 1.34 (0.73-3.21) | 1.67 (0.85-3.46) | 1.46 (0.64-4.14) | 1.34 (1.11-5.4) | 4.85 | 0.70 | |
Time to renal biopsy (mo) | 0 (0 – 2) | 0 (0 – 2) | 0 (0 – 2) | 0 (0 – 2) | 0 (0 – 2) | 0.0 | 0.965 | |
Treatment | ||||||||
RAS blockades (%) | 105 (94.6) | 66 (94.3) | 19 (95.0) | 16 (94.1) | 3 (100.0) | 1 (100.0) | 0.991 | |
Steroid (%) | 47 (42.3) | 23 (32.9) | 13 (65.0) | 7 (41.2) | 3 (100.0) | 1 (100.0) | 0.035 | |
Responder (n) | 25 | 12 | 9 | 2 | 1 | 1 | ||
Resistance (n) | 22 | 11 | 4 | 5 | 2 | 0 | ||
Cyclosporine (%) | 25 (22.5) | 13 (18.6) | 6 (30.0) | 4 (23.5) | 2 (66.7) | 0 (0.0) | 0.431 | |
MMF (n) | 2 | 1 | 0 | 1 | 0 | 0 | ||
Cyclophosphamide (n) | 1 | 1 | 0 | 0 | 0 | 0 | ||